Inhibitory effect of quercetin on matrix metalloproteinase 9 activity Molecular mechanism and structure-activity relationship of the flavonoid-enzyme interaction

European Journal of Pharmacology

Volumn 644, Issue 1-3, 2010, Pages 138-145

  Saragusti, Alejandra C ^a,b   Ortega, María G ^a,b   Cabrera, José L ^a,b   Estrin, Darío A ^a   Marti, Marcelo A ^a,c,d   Chiabrando, Gustavo A ^a,b  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d Instituto de Quimica Fisica de los Materiales Medio Ambiente y Energia   (Argentina)

Author keywords

Diet polyphenol; Docking; Flavonoid; Molecular dynamics; Zymography

Indexed keywords

CHRYSIN; FISETIN; GALANGIN; GELATINASE B; KAEMPFEROL; LUTEOLIN; MORIN; QUERCETIN;

ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; HUMAN CELL; IC 50; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; ZYMOGRAPHY;

ANTIOXIDANTS; BINDING SITES; CELL LINE, TUMOR; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; INHIBITORY CONCENTRATION 50; MATRIX METALLOPROTEINASE 9; MODELS, MOLECULAR; PROTEIN BINDING; QUERCETIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77955769066     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.07.001     Document Type: Article

References (62)

1. Alcocer F., Whitley D., Salazar-Gonzalez J.F., Jordan W.D., Sellers M.T., Eckhoff D.E., Suzuki K., Macrae C., Bland K.I. Quercetin inhibits human vascular smooth muscle cell proliferation and migration. Surgery 2002, 131:198-204.
2. Berendsen H.J.C., Postma J.P.M., Van Gunsteren W.F., DiNola A., Haak J.R. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 1984, 81:3684-3690.
3. Bertini I., Gupta Y.K., Luchinat C., Parigi G., Peana M., Sgheri L., Yuan J. Paramagnetism-based NMR restraints provide maximum allowed probabilities for the different conformations of partially independent protein domains. J. Am. Chem. Soc. 2007, 129:12786-12794.
4. Bode W., Maskos K. Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases. Biol. Chem. 2003, 384:863-872.
5. Bode W., Fernandez-Catalan C., Tschesche H., Grams F., Nagase H., Maskos K. Structural properties of matrix metalloproteinases. Cell. Mol. Life Sci. 1999, 55:639-652.
6. Brambilla D., Mancuso C., Scuderi M.R., Bosco P., Cantarella G., Lempereur L., Di Benedetto G., Pezzino S., Bernardini R. The role of antioxidant supplement in immune system, neoplastic, and neurodegenerative disorders: a point of view for an assessment of the risk/benefit profile. Nutr. J. 2008, 7:29.
7. Cuccioloni M., Mozzicafreddo M., Bonfili L., Cecarini V., Eleuteri A.M., Angeletti M. Natural occurring polyphenols as template for drug design. Focus on serine proteases. Chem. Biol. Drug Des. 2009, 74:1-15.
8. Cuniasse P., Devel L., Makaritis A., Beau F., Georgiadis D., Matziari M., Yiotakis A., Dive V. Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs. Biochimie 2005, 87:393-402.
9. Demeule M., Brossard M., Page M., Gingras D., Beliveau R. Matrix metalloproteinase inhibition by green tea catechins. Biochim. Biophys. Acta 2000, 1478:51-60.
10. Di Castelnuovo A., Rotondo S., Iacoviello L., Donati M.B., De Gaetano G. Meta-analysis of wine and beer consumption in relation to vascular risk. Circulation 2002, 105:2836-2844.
11. Diaz N., Suarez D. Molecular dynamics simulations of matrix metalloproteinase 2: role of the structural metal ions. Biochemistry 2007, 46:8943-8952.
12. Erlund I., Freese R., Marniemi J., Hakala P., Alfthan G. Bioavailability of quercetin from berries and the diet. Nutr. Cancer 2006, 54:13-17.
13. Frisch, M.J., Trucks, G.W., Schlegel, H.B., Gill, P.M.W., Johnson, B.G., Robb, M.A., Cheeseman, J.R., Keith, T., Petersson, G.A., Montgomery, J.A., Raghavachari, K., Al-Laham, M.A., Zakrzewski, V.G., Ortiz, J.V., Foresman, J.B., Cioslowski, J., Stefanov, B.B., Nanayakkara, A., Challacombe, M., Peng, C.Y., Ayala, P.Y., Chen, W., Wong, M.W., Andres, J.L., Replogle, E.S., Gomperts, R., Martin, R.L., Fox, D.J., Binkley, J.S., Defrees, D.J., Baker, J., Stewart, J.P., Head-Gordon, M., Gonzalez, C., Pople, J.A., Gaussian, Inc., Pittsburgh PA, 1998.
14. Giovannini C., Scazzocchio B., Vari R., Santangelo C., D'Archivio M., Masella R. Apoptosis in cancer and atherosclerosis: polyphenol activities. Ann. Ist. Super. Sanità 2007, 43:406-416.
15. Guglielmone H.A., Agnese A.M., Nunez Montoya S.C., Cabrera J.L. Anticoagulant effect and action mechanism of sulphated flavonoids from Flaveria bidentis. Thromb. Res. 2002, 105:183-188.
16. Guglielmone H.A., Agnese A.M., Nunez Montoya S.C., Cabrera J.L. Inhibitory effects of sulphated flavonoids isolated from Flaveria bidentis on platelet aggregation. Thromb. Res. 2005, 115:495-502.
17. Hayek T., Fuhrman B., Vaya J., Rosenblat M., Belinky P., Coleman R., Elis A., Aviram M. Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Arterioscler. Thromb. Vasc. Biol. 1997, 17:2744-2752.
18. Hornak V., Abel R., Okur A., Strockbine B., Roitberg A., Simmerling C. Comparison of multiple amber force fields and development of improved protein backbone parameters. Proteins: Struct. Funct. Genet. 2006, 65:712-725.
19. Hu X., Shelver W.H. Docking studies of matrix metalloproteinase inhibitors: zinc parameter optimization to improve the binding free energy prediction. J. Mol. Graph. Model. 2003, 22:115-126.
20. Humphrey W., Dalke A., Schulten K. VMD: visual molecular dynamics. J. Mol. Graph. 1996, 14(33-38):27-38.
21. Huxley R.R., Neil H.A. The relation between dietary flavonol intake and coronary heart disease mortality: a meta-analysis of prospective cohort studies. Eur. J. Clin. Nutr. 2003, 57:904-908.
22. Kawai Y., Nishikawa T., Shiba Y., Saito S., Murota K., Shibata N., Kobayashi M., Kanayama M., Uchida K., Terao J. Macrophage as a target of quercetin glucuronides in human atherosclerotic arteries: implication in the anti-atherosclerotic mechanism of dietary flavonoids. J. Biol. Chem. 2008, 283:9424-9434.
23. Kiyama R., Tamura Y., Watanabe F., Tsuzuki H., Ohtani M., Yodo M. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors. J. Med. Chem. 1999, 42:1723-1738.
24. Kleiner D.E., Stetler-Stevenson W.G. Quantitative zymography: detection of picogram quantities of gelatinases. Anal. Biochem. 1994, 218:325-329.
25. Knekt P., Jarvinen R., Reunanen A., Maatela J. Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ 1996, 312:478-481.
26. Lang R., Kocourek A., Braun M., Tschesche H., Huber R., Bode W., Maskos K. Substrate specificity determinants of human macrophage elastase (MMP-12) based on the 1.1 A crystal structure. J. Mol. Biol. 2001, 312:731-742.
27. Lee M.R., Duan Y., Kollman P.A. Use of MM-PB/SA in estimating the free energies of proteins: application to native, intermediates, and unfolded villin headpiece. Proteins 2000, 39:309-316.
28. Li Y.L., Xu W.F. Design, synthesis, and activity of caffeoyl pyrrolidine derivatives as potential gelatinase inhibitors. Bioorg. Med. Chem. 2004, 12:5171-5180.
29. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
30. Lu Q., Luo R. A Poisson-Boltzmann dynamics method with nonperiodic boundary condition. J. Chem. Phys. 2003, 119:11035-11047.
31. Maron D.J. Flavonoids for reduction of atherosclerotic risk. Curr. Atheroscler. Rep. 2004, 6:73-78.
32. Matsuda H., Morikawa T., Toguchida I., Yoshikawa M. Structural requirements of flavonoids and related compounds for aldose reductase inhibitory activity. Chem. Pharm. Bull. (Tokyo) 2002, 50:788-795.
33. Middleton E., Kandaswami C., Theoharides T.C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol. Rev. 2000, 52:673-751.
34. Moon S.K., Cho G.O., Jung S.Y., Gal S.W., Kwon T.K., Lee Y.C., Madamanchi N.R., Kim C.H. Quercetin exerts multiple inhibitory effects on vascular smooth muscle cells: role of ERK1/2, cell-cycle regulation, and matrix metalloproteinase-9. Biochem. Biophys. Res. Commun. 2003, 301:1069-1078.
35. Mukamal K.J., Maclure M., Muller J.E., Sherwood J.B., Mittleman M.A. Tea consumption and mortality after acute myocardial infarction. Circulation 2002, 105:2476-2481.
36. Newby A.C. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc. Res. 2006, 69:614-624.
37. Nguyen M., Arkell J., Jackson C.J. Human endothelial gelatinases and angiogenesis. Int. J. Biochem. Cell Biol. 2001, 33:960-970.
38. Ortega M.G., Saragusti A.C., Cabrera J.L., Chiabrando G.A. Quercetin tetraacetyl derivative inhibits LPS-induced nitric oxide synthase (iNOS) expression in J774A.1 cells. Archives of Biochemistry and Biophysics 2010, 498:105-110.
39. Osiecki H. The role of chronic inflammation in cardiovascular disease and its regulation by nutrients. Altern. Med. Rev. 2004, 9:32-53.
40. Osterberg F., Morris G.M., Sanner M.F., Olson A.J., Goodsell D.S. Automated docking to multiple target structures: incorporation of protein mobility and structural water heterogeneity in AutoDock. Proteins 2002, 46:34-40.
41. Pasterkamp G., Schoneveld A.H., Hijnen D.J., de Kleijn D.P., Teepen H., van der Wal A.C., Borst C. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis 2000, 150:245-253.
42. Pavlovsky A.G., Williams M.G., Ye Q.Z., Ortwine D.F., Purchase C.F., White A.D., Dhanaraj V., Roth B.D., Johnson L.L., Hupe D., Humblet C., Blundell T.L. X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity. Protein Sci. 1999, 8:1455-1462.
43. Pearlman D.A., Case D.A., Caldwell J.W., Ross W.S., Cheatham Iii T.E., DeBolt S., Ferguson D., Seibel G., Kollman P. AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules. Comput. Phys. Commun. 1995, 91:1-41.
44. Peters U., Poole C., Arab L. Does tea affect cardiovascular disease? A meta-analysis. Am. J. Epidemiol. 2001, 154:495-503.
45. Pignatelli P., Pulcinelli F.M., Celestini A., Lenti L., Ghiselli A., Gazzaniga P.P., Violi F. The flavonoids quercetin and catechin synergistically inhibit platelet function by antagonizing the intracellular production of hydrogen peroxide. Am. J. Clin. Nutr. 2000, 72:1150-1155.
46. Pirard B., Matter H. Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis. J. Med. Chem. 2006, 49:51-69.
47. Rahat M.A., Marom B., Bitterman H., Weiss-Cerem L., Kinarty A., Lahat N. Hypoxia reduces the output of matrix metalloproteinase-9 (MMP-9) in monocytes by inhibiting its secretion and elevating membranal association. J. Leukoc. Biol. 2006, 79:706-718.
48. Rao B.G. Recent developments in the design of specific matrix metalloproteinase inhibitors aided by structural and computational studies. Curr. Pharm. Des. 2005, 11:295-322.
49. Raso G.M., Meli R., Di Carlo G., Pacilio M., Di Carlo R. Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression by flavonoids in macrophage J774A.1. Life Sci. 2001, 68:921-931.
50. Rice-Evans C.A., Miller N.J., Paganga G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic. Biol. Med. 1996, 20:933-956.
51. Rowsell S., Hawtin P., Minshull C.A., Jepson H., Brockbank S.M., Barratt D.G., Slater A.M., McPheat W.L., Waterson D., Henney A.M., Pauptit R.A. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J. Mol. Biol. 2002, 319:173-181.
52. Ryckaert J.P., Ciccotti G., Berendsen H.J.C. Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 1977, 23:327-341.
53. Sartor L., Pezzato E., Dell'Aica I., Caniato R., Biggin S., Garbisa S. Inhibition of matrix-proteases by polyphenols: chemical insights for anti-inflammatory and anti-invasion drug design. Biochem. Pharmacol. 2002, 64:229-237.
54. Silva M.M., Santos M.R., Caroco G., Rocha R., Justino G., Mira L. Structure-antioxidant activity relationships of flavonoids: a re-examination. Free Radic. Res. 2002, 36:1219-1227.
55. Stawowy P., Meyborg H., Stibenz D., Borges Pereira Stawowy N., Roser M., Thanabalasingam U., Veinot J.P., Chretien M., Seidah N.G., Fleck E., Graf K. Furin-like proprotein convertases are central regulators of the membrane type matrix metalloproteinase-pro-matrix metalloproteinase-2 proteolytic cascade in atherosclerosis. Circulation 2005, 111:2820-2827.
56. Tuccinardi T., Martinelli A., Nuti E., Carelli P., Balzano F., Uccello-Barretta G., Murphy G., Rossello A. Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides. Bioorg. Med. Chem. 2006, 14:4260-4276.
57. van't Veer P., Jansen M.C., Klerk M., Kok F.J. Fruits and vegetables in the prevention of cancer and cardiovascular disease. Public Health Nutr. 2000, 3:103-107.
58. Walker E.H., Pacold M.E., Perisic O., Stephens L., Hawkins P.T., Wymann M.P., Williams R.L. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell 2000, 6:909-919.
59. Wang J., Cieplak P., Kollman P.A. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules?. J. Comput. Chem. 2000, 21:1049-1074.
60. Wang J., Wolf R.M., Caldwell J.W., Kollman P.A., Case D.A. Development and testing of a general amber force field. J. Comput. Chem. 2004, 25:1157-1174.
61. Welton A.F., Hurley J., Will P. Flavonoids and arachidonic acid metabolism. Prog. Clin. Biol. Res. 1988, 280:301-312.
62. Zhang S., Yang X., Coburn R.A., Morris M.E. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem. Pharmacol. 2005, 70:627-639.